Skip to main content
. Author manuscript; available in PMC: 2021 Sep 9.
Published in final edited form as: Nature. 2020 Sep 9;585(7825):447–452. doi: 10.1038/s41586-020-2690-1

Figure 4. TRIM37 overexpression delays centrosome separation in late G2 phase and promotes mitotic errors.

Figure 4.

(A) Quantification of the distance between the two centrosomes at NEBD in control MCF-7, MDA-MB-361, MDA-MB-231, and MDA-MB-436 cells compared to those expressing a TRIM37-shRNA. Data acquired across n = ≥3, biological replicates, each with 8 - 45 cells. P values, unpaired two-tailed t-test. Mean ± s.e.m.

(B) Quantification of mitotic phenotypes in control MCF-7, MDA-MB-361, MDA-MB-231, and MDA-MB-436 cells compared to those expressing a TRIM37-shRNA. Data acquired across n = 3, biological replicates, each with >40 cells. P values, unpaired two-tailed t-test. Mean ± s.e.m.

(C) Quantification of mitotic duration in control MCF-7, MDA-MB-361, MDA-MB-231, and MDA-MB-436 cells compared to those expressing a TRIM37-shRNA. Triangles represent the mean for each biological replicate; coloured circles show individual data points from each of the replicates. Data acquired across n = 3, biological replicates, each with >40 cells. P values, unpaired two-tailed t-test. Mean ± s.e.m.

(D) A model illustrating the synthetic lethal effect of PLK4 inhibition with TRIM37 overexpression in 17q23-amplified breast cancer cells.